These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 16396064

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up.
    Valkonen H, Waris M, Ruohola A, Ruuskanen O, Heikkinen T.
    Allergy; 2009 Sep; 64(9):1359-65. PubMed ID: 19416146
    [Abstract] [Full Text] [Related]

  • 43. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 44. Bronchiolitis: from empiricism to scientific evidence.
    Carraro S, Zanconato S, Baraldi E.
    Minerva Pediatr; 2009 Apr; 61(2):217-25. PubMed ID: 19322125
    [Abstract] [Full Text] [Related]

  • 45. Respiratory syncytial virus bronchiolitis: prevention and treatment.
    Faber TE, Kimpen JL, Bont LJ.
    Expert Opin Pharmacother; 2008 Oct; 9(14):2451-8. PubMed ID: 18778183
    [Abstract] [Full Text] [Related]

  • 46. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls.
    Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Björkstén B.
    Pediatrics; 1995 Apr; 95(4):500-5. PubMed ID: 7700748
    [Abstract] [Full Text] [Related]

  • 47. Prophylaxis for respiratory syncytial virus bronchiolitis.
    Nadal D, Berger C, Aebi C, Kind C.
    Lancet; 1999 Dec 04; 354(9194):1997. PubMed ID: 10622321
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Effectiveness of palivizumab in children with childhood interstitial lung disease: The French experience.
    Drummond D, Thumerelle C, Reix P, Fayon M, Epaud R, Clement A, Mahloul M, Habouria D, Delacourt C, Hadchouel A.
    Pediatr Pulmonol; 2016 Jul 04; 51(7):688-95. PubMed ID: 26636747
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
    Blanken M, Rovers M, Sanders E, Bont L.
    Contemp Clin Trials; 2012 Nov 04; 33(6):1287-92. PubMed ID: 22820319
    [Abstract] [Full Text] [Related]

  • 57. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL, Palivizumab Long-Term Respiratory Outcomes Study Group.
    J Pediatr; 2007 Jul 04; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [Abstract] [Full Text] [Related]

  • 58. Respiratory tract infections caused by respiratory syncytial virus in children. Diagnosis and treatment.
    Van Woensel JB, Kimpen JL, Brand PL.
    Minerva Pediatr; 2001 Apr 04; 53(2):99-106. PubMed ID: 11404731
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.